-
ATM Inhibition and Metabolic Therapy Synergy in Ovarian Canc
2026-05-11
This study demonstrates that ATM kinase inhibition, when combined with the PPARα agonist fenofibrate, synergistically induces senescence in high grade serous ovarian cancer (HGSOC) cell lines. The findings highlight a novel therapeutic strategy for HR-proficient HGSOC, a subgroup resistant to current DNA damage-based therapies.
-
Olaparib (AZD2281): PARP Inhibition for BRCA-Driven Cancer R
2026-05-10
Olaparib (AZD2281) is a highly selective PARP-1/2 inhibitor with nanomolar potency, enabling precise DNA damage response assays and targeted therapy development for BRCA-mutant cancers. APExBIO’s formulation supports robust radiosensitization and translational workflows in oncology research. Its validated mechanisms, benchmarks, and workflow parameters are essential for preclinical and translational cancer research.
-
Vorinostat: Applied Epigenetic Modulation in Cancer Research
2026-05-09
Vorinostat (suberoylanilide hydroxamic acid) empowers researchers to precisely dissect HDAC inhibition, apoptosis, and chromatin remodeling in cancer models. This article delivers actionable workflows, troubleshooting insights, and protocol optimizations for robust, reproducible results in experimental oncology and beyond.
-
Dimethyloxalylglycine (DMOG): Technical Workflow and QC Guid
2026-05-08
Dimethyloxalylglycine (DMOG) is a cell-permeable, competitive inhibitor for controlled stabilization of hypoxia-inducible factor (HIF) in in vitro and in vivo research. It facilitates precise modeling of hypoxia and immune regulation pathways, provided that strict solubility and handling protocols are followed. DMOG should not be used for clinical or diagnostic purposes.
-
Lamotrigine in Sodium Channel Signaling: Protocols & Pitfall
2026-05-08
Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) from APExBIO delivers high-purity, reproducible results in both neuro and cardiac sodium channel research. This article details optimized workflows, practical troubleshooting tips, and key evidence to empower rigorous, high-fidelity assay implementation.
-
Meropenem Trihydrate in Resistance Profiling & Infection Mod
2026-05-07
Leverage Meropenem trihydrate as a gold-standard carbapenem antibiotic to empower high-fidelity resistance phenotyping and infection model workflows. This article delivers actionable protocol enhancements, troubleshooting guidance, and cross-study insights—bridging advanced metabolomics with practical bench research for next-generation antimicrobial investigations.
-
SAG: Mechanistic Insights and Strategic Use in Hedgehog Modu
2026-05-07
Explore how Smoothened Agonist (SAG) operates as a potent Smoothened receptor agonist, empowering advanced Hedgehog pathway research. This article reveals mechanistic nuances, protocol optimization, and evidence-based guidance beyond standard workflows.
-
Applied Use of KU-55933 ATM Kinase Inhibitor in DNA Damage R
2026-05-06
KU-55933’s high selectivity for ATM kinase unlocks precise control of DNA damage response in both cancer and advanced iPSC-based models, enabling reproducible cell cycle arrest and metabolic profiling. This article offers stepwise protocol guidance, troubleshooting strategies, and actionable insights for translational researchers seeking robust, quantifiable results.
-
UBQLN2 and HSP70 Facilitate Parkin-Mediated Mitophagy via OM
2026-05-06
This study uncovers a mechanistic link between UBQLN2, HSP70, and Parkin in the regulation of mitophagy, specifically highlighting how these proteins cooperate to facilitate outer mitochondrial membrane rupture and subsequent mitochondrial clearance. The findings provide new insights into the molecular basis of neurodegeneration in ALS/FTD and offer a refined understanding of mitochondrial quality control pathways.
-
Olaparib (AZD2281) in DNA Damage Response and Cancer Therapy
2026-05-05
Olaparib (AZD2281) stands out as a selective PARP inhibitor, enabling precise DNA damage response assays and advancing targeted therapy research for BRCA-associated cancers. Here, we detail practical protocols, troubleshoot common pitfalls, and contextualize recent findings on platinum resistance to maximize research outcomes.
-
KU-60019: ATM Kinase Inhibitor Strategies for Glioma Researc
2026-05-05
Unlock the full experimental power of KU-60019, a next-generation ATM kinase inhibitor, for glioma radiosensitization and migration inhibition. This guide delivers actionable workflows, key troubleshooting strategies, and data-driven tips for maximizing reproducibility and scientific insight in DNA damage response research.
-
CP-673451: Selective PDGFRα/β Inhibitor Empowering Cancer Re
2026-05-04
CP-673451 stands out as a rigorously validated, selective PDGFRα/β inhibitor for dissecting angiogenesis and tumor progression—especially in challenging ATRX-deficient glioma models. This article provides actionable workflows, troubleshooting insights, and data-driven protocol parameters for maximizing experimental reproducibility in cancer research.
-
Applied Workflows with EZ Cap™ Firefly Luciferase mRNA
2026-05-04
EZ Cap™ Firefly Luciferase mRNA, featuring a Cap 1 structure, delivers robust, sustained bioluminescent expression for translation efficiency, gene regulation, and in vivo imaging assays. This article bridges cutting-edge LNP delivery research with actionable protocols and troubleshooting, empowering scientists to achieve reproducible results even in challenging experimental contexts.
-
Fasudil (HA-1077) HCl: Optimizing ROCK Inhibition Workflows
2026-05-03
Fasudil (HA-1077) HCl from APExBIO empowers researchers with highly selective, reproducible Rho/ROCK pathway inhibition for cancer and disease modeling. This guide delivers actionable protocols, troubleshooting strategies, and advanced use-case insights, ensuring robust cell proliferation and migration assays.
-
Applied Workflows with EZ Cap Cy5 Firefly Luciferase mRNA
2026-05-02
EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) offers simultaneous real-time mRNA tracking and robust luciferase reporter assays, streamlining both delivery optimization and intracellular fate studies. Its dual-modality readout and reduced immunogenicity help researchers rapidly troubleshoot transfection protocols and advance gene therapy workflows.